206 related articles for article (PubMed ID: 12497001)
1. Microvessel density in prostate carcinoma.
Bono AV; Celato N; Cova V; Salvadore M; Chinetti S; Novario R
Prostate Cancer Prostatic Dis; 2002; 5(2):123-7. PubMed ID: 12497001
[TBL] [Abstract][Full Text] [Related]
2. Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease.
Di Lorenzo G; De Placido S; Autorino R; De Laurentiis M; Mignogna C; D'Armiento M; Tortora G; De Rosa G; D'Armiento M; De Sio M; Bianco AR; D'Armiento FP
Prostate Cancer Prostatic Dis; 2005; 8(1):54-9. PubMed ID: 15655565
[TBL] [Abstract][Full Text] [Related]
3. Microvessel density as a predictor of PSA recurrence after radical prostatectomy. A comparison of CD34 and CD31.
de la Taille A; Katz AE; Bagiella E; Buttyan R; Sharir S; Olsson CA; Burchardt T; Ennis RD; Rubin MA
Am J Clin Pathol; 2000 Apr; 113(4):555-62. PubMed ID: 10761458
[TBL] [Abstract][Full Text] [Related]
4. Genetic aberrations in prostate carcinoma detected by comparative genomic hybridization and microsatellite analysis: association with progression and angiogenesis.
Strohmeyer DM; Berger AP; Moore DH; Bartsch G; Klocker H; Carroll PR; Loening SA; Jensen RH
Prostate; 2004 Apr; 59(1):43-58. PubMed ID: 14991865
[TBL] [Abstract][Full Text] [Related]
5. Expression of different vascular endothelial markers in prostate cancer and BPH tissue: an immunohistochemical and clinical evaluation.
Trojan L; Thomas D; Friedrich D; Grobholz R; Knoll T; Alken P; Michel MS
Anticancer Res; 2004; 24(3a):1651-6. PubMed ID: 15274336
[TBL] [Abstract][Full Text] [Related]
6. Expression of bFGF, VEGF and c-met and their correlation with microvessel density and progression in prostate carcinoma.
Strohmeyer D; Strauss F; Rössing C; Roberts C; Kaufmann O; Bartsch G; Effert P
Anticancer Res; 2004; 24(3a):1797-804. PubMed ID: 15274358
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of microvessel density and mast cell density for the survival of Thai patients with primary colorectal cancer.
Yodavudh S; Tangjitgamol S; Puangsa-art S
J Med Assoc Thai; 2008 May; 91(5):723-32. PubMed ID: 18672639
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
Bhatti SS; Kumar L; Dinda AK; Dawar R
Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
[TBL] [Abstract][Full Text] [Related]
9. Is tumor vascularity in prostate core biopsies a predictor of PSA recurrence after radical prostatectomy?
Khatami A; Pihl CG; Norrby K; Hugosson J; Damber JE
Acta Oncol; 2005; 44(4):362-8. PubMed ID: 16120545
[TBL] [Abstract][Full Text] [Related]
10. A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes?
Thong AE; Shikanov S; Katz MH; Gofrit ON; Eggener S; Zagaja GP; Shalhav AL; Zorn KC
J Urol; 2008 Dec; 180(6):2436-40. PubMed ID: 18930486
[TBL] [Abstract][Full Text] [Related]
11. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.
Nelson BA; Shappell SB; Chang SS; Wells N; Farnham SB; Smith JA; Cookson MS
BJU Int; 2006 Jun; 97(6):1169-72. PubMed ID: 16686706
[TBL] [Abstract][Full Text] [Related]
12. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of primary Gleason pattern 4 in patients with Gleason score 7 tumours treated with radical prostatectomy.
Khoddami SM; Shariat SF; Lotan Y; Saboorian H; McConnell JD; Sagalowsky AI; Roehrborn CG; Koeneman KS
BJU Int; 2004 Jul; 94(1):42-6. PubMed ID: 15217428
[TBL] [Abstract][Full Text] [Related]
14. Does the tertiary Gleason pattern influence the PSA progression-free interval after retropubic radical prostatectomy for organ-confined prostate cancer?
van Oort IM; Schout BM; Kiemeney LA; Hulsbergen CA; Witjes JA
Eur Urol; 2005 Oct; 48(4):572-6. PubMed ID: 16046051
[TBL] [Abstract][Full Text] [Related]
15. The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy.
Cheng L; Koch MO; Juliar BE; Daggy JK; Foster RS; Bihrle R; Gardner TA
J Clin Oncol; 2005 May; 23(13):2911-7. PubMed ID: 15860849
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer.
Carver BS; Bianco FJ; Scardino PT; Eastham JA
J Urol; 2006 Aug; 176(2):564-8. PubMed ID: 16813890
[TBL] [Abstract][Full Text] [Related]
17. A pathological reassessment of organ-confined, Gleason score 6 prostatic adenocarcinomas that progress after radical prostatectomy.
Miyamoto H; Hernandez DJ; Epstein JI
Hum Pathol; 2009 Dec; 40(12):1693-8. PubMed ID: 19683331
[TBL] [Abstract][Full Text] [Related]
18. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy.
Bettencourt MC; Bauer JJ; Sesterhenn IA; Connelly RR; Moul JW
J Urol; 1998 Aug; 160(2):459-65. PubMed ID: 9679898
[TBL] [Abstract][Full Text] [Related]
19. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M
Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491
[TBL] [Abstract][Full Text] [Related]
20. Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy.
Walz J; Chun FK; Klein EA; Reuther A; Graefen M; Huland H; Karakiewicz PI
Eur Urol; 2009 Feb; 55(2):412-19. PubMed ID: 19027223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
